Endogenous abundance of subpopulations from differentiation states and subsequent to short-term cisplatin treatment. Original flow cytometry data displaying abundance of CD90, CD44, and CD49f positive cells in 11 UCCs corresponding to the summarized data in Fig. 1d. Unstained cells were used to set gates for positively stained cells. Subsequent to short-term treatment with cisplatin (STT, 72 h) most cell lines displayed increased numbers of CD90+ cells as also illustrated in Fig. 4b; representative results from biological triplicates. STT: Short-term cisplatin treatment. (TIF 4559 kb
Figure S1. (A) (PANEL1) Table of 1286 ccRCC patient distribution: 1013 tumor free patients at 36 mon...
Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. Representative...
Characteristics of CART-133 cells. (A) Schematic representation of anti-CD133 CAR, not to scale. (B)...
CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. Original flow cytometry data for abun...
Activation of WNT-signalling may contribute to survival of UCCs upon long-term cisplatin treatment. ...
Primer sequences for quantitative real-time-PCR. Sequences of primers (5′-3′) used for quantitative ...
Figure S1. Analysis of Cisplatin effect on healthy donors CD4+ T cells in vitro. CD4+ T cells were i...
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
SP differentiation assay for evaluation of CSC enrichment in TOV21G and SKOV3. A & B. Quantification...
Applied strategy to determine cell cycle phases and cell cycle phase-specific H2AX phosphorylation l...
Applied strategy to determine cell cycle phases of subpopulations by flow cytometry. Flow cytometric...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
Retreatment of the pooled surviving U-1810-clones from a first round of clonogenic survival, where t...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
Figure S1. (A) (PANEL1) Table of 1286 ccRCC patient distribution: 1013 tumor free patients at 36 mon...
Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. Representative...
Characteristics of CART-133 cells. (A) Schematic representation of anti-CD133 CAR, not to scale. (B)...
CD90+ UCCs do not exhibit a distinct stem cell-like phenotype. Original flow cytometry data for abun...
Activation of WNT-signalling may contribute to survival of UCCs upon long-term cisplatin treatment. ...
Primer sequences for quantitative real-time-PCR. Sequences of primers (5′-3′) used for quantitative ...
Figure S1. Analysis of Cisplatin effect on healthy donors CD4+ T cells in vitro. CD4+ T cells were i...
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
SP differentiation assay for evaluation of CSC enrichment in TOV21G and SKOV3. A & B. Quantification...
Applied strategy to determine cell cycle phases and cell cycle phase-specific H2AX phosphorylation l...
Applied strategy to determine cell cycle phases of subpopulations by flow cytometry. Flow cytometric...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
Retreatment of the pooled surviving U-1810-clones from a first round of clonogenic survival, where t...
Supplementary figure 1. Effects of cisplatin on viability of NRK52E cells and HK-2 cells.NRK52E cell...
Figure S1. (A) (PANEL1) Table of 1286 ccRCC patient distribution: 1013 tumor free patients at 36 mon...
Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. Representative...
Characteristics of CART-133 cells. (A) Schematic representation of anti-CD133 CAR, not to scale. (B)...